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Abstract
Background Greater drug content requirements for
extended-release (ER) opioids necessitate greater protec-
tion against dose dumping. Hydrocodone ER employs the
CIMA Abuse-Deterrence Technology platform, which
provides resistance against rapid release of the active
moiety when the tablet is manipulated or taken with
alcohol.
Objective Assess effects of alcohol on hydrocodone ER
pharmacokinetics.
Study Design Open-label, crossover (January 25–April
30, 2010).
Setting Single center.
Participants Forty healthy adults.
Intervention Subjects received all four treatments in a
randomized manner (separated by a minimum 5-day
washout): hydrocodone ER 15 mg with 240 mL water and
240 mL orange juice containing 4, 20, and 40 % alcohol in
a fasted state. Naltrexone was administered to minimize
opioid-related adverse events.
Main Outcome Measure Effect of alcohol on pharma-
cokinetics of hydrocodone ER assessed by comparing
systemic exposure [maximum plasma drug concentration
(Cmax) and area under the plasma drug concentration-ver-
sus-time curve from time 0 to infinity (AUC0–?)] after
administration with alcohol or with water.
Results Geometric means ratios of hydrocodone ER with
4, 20, and 40 % alcohol relative to water were 1.05, 1.09,
and 1.14, respectively, for Cmax and 1.07, 1.13, and 1.17,
respectively, for AUC0–?. All 90 % confidence intervals
for these geometric means ratios fell within the limits of
0.8 and 1.25. Increasing alcohol concentrations did not
notably affect systemic exposure but were associated with
increased adverse events.
Conclusions Hydrocodone ER tablets were resistant to
dose dumping when administered with alcohol in healthy
subjects based on similar systemic exposures observed
across all treatments.
Key Points
Alcohol should not be consumed concurrently with
opioid therapy.
Hydrocodone ER formulated with CIMA ADT
appears to be resistant to dose dumping when
administered with alcohol, as demonstrated by
similar systemic exposures after administration of
hydrocodone ER with increasing concentrations of
alcohol (4, 20, and 40 %).
Results suggest that concomitant alcohol
consumption has little or no effect on the overall
pharmacokinetic profile of hydrocodone ER.
At the time of this study, MD was an employee of Cephalon, Inc.,
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1 Introduction
Opioids are widely used for the treatment of chronic pain
associated with cancer or end-of-life pain and are being
increasingly used for chronic non-cancer pain. However,
the potential for abuse and misuse remains a concern with
opioids [1]. In studies of patients taking opioids for chronic
non-cancer pain, approximately 30 % of patients have
demonstrated opioid or other substance misuse [2, 3]. The
concomitant use of alcohol and opioids is of particular
concern, given that a personal or family history of alcohol
abuse is strongly predictive of the misuse of opioids for
chronic pain [1]. In 2011, of the 606,653 emergency
department visits associated with drug misuse or abuse
involving drugs and alcohol taken together, 103,730
(17.1 %) were for opioid products [4].
Extended-release (ER) opioid formulations typically
contain a higher unit dose of an opioid than immediate-
release formulations, and some of those formulations
exhibit higher solubility in ethanol than in water. Thus,
there is the potential for concomitant use of an ER opioid
formulation and alcohol that can lead to rapid release of the
opioid (known as dose dumping) and possible overdose [5].
Recently, concerns have been raised in the scientific and
regulatory arenas over the potential for alcohol-induced
dose dumping with ER opioid formulations [6, 7], and this
concern has led to the withdrawal of one controlled-release
formulation of hydromorphone [5].
Until recently, hydrocodone was available for the
treatment of pain only in immediate-release formulations in
combination with other analgesics (e.g. acetaminophen,
ibuprofen) [8]. A single-agent, ER formulation of hydro-
codone bitartrate (Teva Pharmaceuticals, Frazer, PA, USA)
has been developed to provide optimal pain relief with
twice-daily dosing. However, given the increased drug
content required for an ER formulation and the previously
noted concerns related to alcohol-induced dose dumping,
this novel hydrocodone ER formulation was developed
using CIMA Abuse Deterrence Technology (ADT)
(CIMA Labs, Inc., Brooklyn Park, MN). The CIMA ADT
platform provides resistance against rapid release of the
active moiety when the tablet is manipulated or taken with
alcohol, potentially reducing product misuse [9]. In the
CIMA ADT process, hydrocodone bitartrate is granulated
with a high polymer content and is subsequently coated
with a polymeric film to ensure controlled release of
hydrocodone over an extended period while limiting the
release of active drug when either crushed or exposed to
solvents [9]. The polymer-coated granules are compressed
into tablets in combination with a gelling matrix that fur-
ther controls the release of hydrocodone and provides
additional resistance to dose dumping when tablets are
taken with alcohol.
This study was conducted to assess the effect of
increasing concentrations of alcohol on the pharmacoki-
netics of hydrocodone ER.
2 Methods
This phase 1, single-center, randomized, open-label,
crossover study was designed to assess the effect of alcohol
on the pharmacokinetics of hydrocodone ER in healthy
adults. This study was approved by the institutional review
board and conducted in full accordance with the Good
Clinical Practice: Consolidated Guidelines approved by the
International Conference on Harmonisation [10]. Written
informed consent was obtained from all subjects before
study participation.
2.1 Subjects
Healthy men and women between 21 and 45 years of age
with a body mass index between 20 and 30 kg/m2 and a
history of moderate alcohol consumption (7–21 units of
alcohol per week; 1 unit = 1 oz hard liquor, 5 oz wine, or
8 oz beer) were eligible to participate. Women were
required to be surgically sterile for C2 years, 2 years
postmenopausal, or using a medically acceptable method of
contraception during and for 30 days after the study.
Subjects were excluded if they had any clinically sig-
nificant uncontrolled medical condition; a history of drug
or alcohol abuse or habitual consumption of[21 units of
alcohol per week; clinically significant abnormalities in
laboratory, electrocardiogram, or physical examination
findings; or any disorder that would interfere with medi-
cation absorption, distribution, metabolism, or excretion.
Subjects were also excluded if they had used any systemic
or topical prescription or nonprescription medication (ex-
cluding acetaminophen and ibuprofen) within 2 weeks of
the first dose of hydrocodone ER; had donated blood
([450 mL) or experienced significant blood loss within
56 days of the first dose of hydrocodone ER; had abnormal
heart rate or blood pressure; had consumed food or bev-
erages containing C600 mg of caffeine (or C5 cups of
coffee) per day within 2 weeks of the first dose of hydro-
codone ER; had used nicotine products within 12 months;
had used topical or oral nicotine cessation products within
3 months of the first dose of hydrocodone ER; or had a
history of hypersensitivity or idiosyncratic reaction to
hydrocodone, its related compounds, other opioids, or
naltrexone.
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2.2 Study Design
Healthy subjects were randomized in five different treat-
ment sequences to receive 15 mg of hydrocodone ER with
240 mL of water (under fasting conditions), with 240 mL
of orange juice containing 4, 20, or 40 % alcohol (v/v,
under fasting conditions), and with 240 mL of water
(under fed conditions). Data for hydrocodone ER
administered with water under fed conditions are not
relevant to the current discussion and are not reported in
this paper. The alcohol concentrations were specifically
selected to allow for assessment of a broad range of
alcohol exposures. Participants received each regimen
once, separated by a washout period of 7 days, and had to
consume all water or alcohol within 20 min of adminis-
tration of hydrocodone ER. Subjects took a single, 50-mg
tablet of naltrexone 15 and 3 h before and 9 and 21 h after
each administration of hydrocodone ER to block opioid
receptors and minimize opioid-related adverse events
(AEs). Blood samples (3.5 mL) were collected for quan-
titative blood alcohol concentration measurements
immediately before and 1 h after administration of
hydrocodone ER in each treatment period. Subjects were
withdrawn from the respective treatment period if they
vomited within 2.5 h of receiving hydrocodone ER and
were permitted to participate in subsequent treatment
periods at the discretion of the investigator and medical
monitor. Subjects remained in the study center from the
day prior to hydrocodone ER administration through 72 h
postdose and were asked to return to the study center for a
follow-up visit 48–72 h after their last discharge from the
center.
2.2.1 Sample Collection and Analytical Methods
Venous blood samples (3 mL) for pharmacokinetics
were collected by venipuncture or indwelling catheter
approximately 5 min before administration (pre-dose)
and 15, 30, and 45 min and 1, 1.25, 1.5, 1.75, 2, 2.25,
2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 18, 24, 30, 36, 48, 60, and
72 h postdose. The samples were collected into K2EDTA
tubes and chilled pending centrifugation to separate
plasma, which was subsequently stored at approximately
-25 C. The samples were shipped on dry ice to Phar-
maceutical Product Development, LLC (Richmond, VA,
USA), where they were analyzed for hydrocodone and
its active metabolite, hydromorphone, using a validated
high-performance liquid chromatography method with
tandem mass spectrometric detection. The validated
ranges of the method for hydrocodone and hydromor-
phone were 0.100–100 ng/mL and 0.0500–50.0 ng/mL,
respectively.
2.3 Pharmacokinetic Analyses
The pharmacokinetic parameters assessed for hydrocodone
ER and its active metabolite, hydromorphone (when fea-
sible), included maximum plasma drug concentration
(Cmax), without interpolation; time to Cmax (tmax); area
under the plasma drug concentration-versus-time curve
(AUC) from time 0 to 2 h (AUC0–2); AUC from time 0 to
12 h (AUC0–12); AUC from time 0 to infinity (AUC0–?);
percentage extrapolation, calculated as (AUC0–?–
AUC0–t)/(AUC0–?) 9 100, where AUC0–t is the AUC
from time 0 to the time of last measurable plasma drug
concentration; and terminal elimination half-life (t).
2.4 Safety and Tolerability
Safety and tolerability were assessed by evaluating AEs,
clinical laboratory data, 12-lead electrocardiogram data,
physical examination findings, vital signs (pulse, blood
pressure, and respiratory rate), oxyhemoglobin saturation
(SpO2), and concomitant medications. Treatment-related
AEs were defined as those possibly or probably related to
study treatment. AEs were assessed and documented for
the duration of the study through to 48–72 h after last
discharge from the study center.
2.5 Statistical Methods
Up to 40 healthy subjects were planned to be enrolled in
this study, with the intent that approximately 30 subjects
would complete the study. This sample size was anticipated
to provide at least 80 % power to detect bioequivalence if
the intrasubject standard deviation of a natural log-trans-
formed pharmacokinetic parameter was 0.283 or lower.
The safety and pharmacokinetic analysis sets were
prespecified. The safety analysis set included all subjects
who were randomized to treatment and received at least
one dose of hydrocodone ER. The pharmacokinetic anal-
ysis set included all subjects in the safety analysis set who
had sufficient data for determining pharmacokinetic
parameters for the treatment with water and with at least
one other treatment.
Pharmacokinetic parameters were summarized with
descriptive statistics. The effect of alcohol on the phar-
macokinetics of hydrocodone ER was assessed by com-
paring systemic exposure (Cmax and AUC) of hydrocodone
after administration with alcohol to that with water. The
log-transformed values of these parameters were analyzed
using the analysis of variance model (ANOVA), which
included treatment, treatment sequence, and period as the
fixed effects and subject as a random effect (post hoc). The
two-sided 90 % CIs for ratios of geometric means of Cmax
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and AUC for 4, 20, and 40 % alcohol versus water were
calculated. As recommended by industry bioequivalence
guidelines [11], if the 90 % CIs were within the limits of
0.8–1.25, then no interaction with alcohol was declared.
Box and whisker plots were created post hoc to depict Cmax
and AUC0–? data by alcohol concentration.
3 Results
3.1 Subjects
Of the 102 subjects screened, 40 were enrolled and ran-
domized and 39 received at least one dose of hydrocodone
ER and were included in the safety analysis set (Fig. 1).
Thirty-one subjects completed all four sampling periods,
and 30 subjects were included in the pharmacokinetic
analysis set. (One subject vomited within 1 h of receiving
hydrocodone ER and water and was not eligible for phar-
macokinetic comparison.) The majority of participants
were men (90 %) and white (87 %), with a median (range)
age of 30 (21–44) years and a median (range) body mass
index of 25.7 kg/m2 (20.9–29.9 kg/m2). In total, nine
subjects discontinued from the study: five for noncompli-
ance to study procedures, three for withdrawal of consent,
and one for an AE (vomiting after receiving naltrexone but
before receiving the first dose of hydrocodone ER).
3.2 Pharmacokinetics
Administration of hydrocodone ER with 4, 20, or 40 %
alcohol did not have a notable effect on the pharmacoki-
netic profile compared with administration with water.
Figures 2 and 3 present the plasma concentration-versus-
time profiles through 72 h and through 12 h (planned
dosing interval) after administration of hydrocodone ER
with water (0 % alcohol) or with 4, 20, or 40 % alcohol,
respectively. No appreciable differences in the curves of
the mean plasma hydrocodone concentration-versus-time
profiles were observed when hydrocodone ER was
administered with up to 40 % alcohol. A summary of
pharmacokinetic parameters for hydrocodone ER after
administration with water and with varying amounts of
alcohol is presented in Table 1. Parameters [including
measures of systemic exposure (AUC0–? range
198.2–228.2 ngh/mL), Cmax (range 12.8–14.0 ng/mL),
and tmax (range 6.0–8.0 h)] were generally comparable
among treatment groups. Cmax and AUC0–? data by
alcohol concentration are shown in Fig. 4.
Subjects screened (n=102) 
Subjects randomized (n=40) 
Screened but not randomized(n=62) 
Inclusion criteria not met (n=25) 
Exclusion criteria met (n=9) 
Consent withdrawn (n=3) 
Lost to follow-up (n=1) 
Other (n=24) 
Received a dose of study drug (n=39) 
Evaluable for safety (n=39) 





Reason for withdrawal 
Adverse event (n=1) 
Consent withdrawn (n=3) 
Noncompliance with study procedures (n=5) 
Fig. 1 Subject disposition
Fig. 2 Mean (SD) plasma hydrocodone concentration-versus-time
profiles through 72 h in healthy subjects (pharmacokinetic analysis
set)
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Analysis results based on ANOVA for Cmax and
AUC0–? of hydrocodone are presented in Table 2. Sys-
temic exposure was comparable when hydrocodone ER
was administered with alcohol (4, 20, or 40 %) or with
water. The ratios of the geometric means of hydrocodone
exposure with concurrent alcohol relative to water ranged
from 1.05 to 1.17. The 90 % CIs for the ratios of geometric
means of Cmax and AUC0–? fell within the limits of 0.8
and 1.25 for 4, 20, and 40 % alcohol relative to water.
Systemic exposure to hydromorphone was approxi-
mately 1–2 % of that observed for hydrocodone for all
regimens.
3.3 Safety and Tolerability
All subjects were administered naltrexone to limit opioid-
related AEs. No serious AEs, including deaths, were
reported during the study. One subject discontinued from
the study due to vomiting; however, this subject was
withdrawn after receiving two doses of naltrexone but
before receiving the first dose of hydrocodone ER.
In total, 30 subjects (77 %) reported at least one AE. The
incidence of AEs increased with increasing concentrations of
alcohol (25, 57, and 61 % with 4, 20, and 40 % alcohol,
respectively). All AEs were mild or moderate in severity and
the most frequently occurring AEs were nausea (46 %),
headache (44 %), vomiting (33 %), feeling drunk (28 %),
and dizziness (26 %) (Table 3). AEs considered to be
treatment-related by the investigator were reported in 22
(56 %) subjects; the most common were nausea (38 %),
headache (36 %), and vomiting (26 %). The incidence of
treatment-related AEs was greater after 20 % and 40 %
alcohol (43 and 48 %, respectively) than after water (22 %)
or 4 % alcohol (11 %). AEs were generally consistent with
those associated with alcohol consumption.
No clinically significant changes in SpO2, hematology,
chemistry, urinalysis, or electrocardiogram results were
reported. Eight subjects had clinically significant decreases
in systolic blood pressure (B85 mmHg and decrease from
baseline of C20 mmHg) and one subject had a clinically
significant increase in diastolic blood pressure
(C105 mmHg and increase from baseline of C15 mmHg)
at least once during the study. None of these blood pressure
changes were reported as AEs. Of the 28 subjects with
clinically significant respiratory rates (\10 breaths/min-
ute), none of the decreases were reported as AEs or were
suggestive of respiratory depression.
4 Discussion
The package inserts of opioid medications include warn-
ings on the potentially additive or synergistic effects of
concomitant alcohol use on central nervous system
Fig. 3 Mean (SD) plasma hydrocodone concentration-versus-time
profiles through 12 h in healthy subjects (pharmacokinetic analysis
set)
Table 1 Mean (SD) plasma hydrocodone pharmacokinetic parameters by treatment: pharmacokinetic analysis set
Pharmacokinetic parameter Hydrocodone ER 15 mg
Water (n = 30) 4 % alcohol (n = 30) 20 % alcohol (n = 27) 40 % alcohol (n = 24)
Cmax (ng/mL) 12.8 (3.2) 13.6 (3.6) 14.0 (3.9) 13.6 (2.9)
tmax (h)
a 8.0 (5.0,10.0) 8.0 (5.0, 12.0) 8.0 (4.0, 10.0) 6.0 (3.5, 12.0)
AUC0–2 (ngh/mL) 4.0 (1.6) 3.3 (1.5) 4.8 (1.9) 5.5 (2.2)
AUC0–12 (ngh/mL) 105.1 (26.7) 107.9 (27.3) 116.1 (29.2) 113.0 (22.7)
AUC0–? (ngh/mL) 198.2 (53.8) 214.3 (53.2) 228.2 (63.5) 219.7 (58.7)
Extrapolation (%) 1.5 (0.9) 1.3 (0.7) 1.2 (0.7) 1.5 (1.0)
t (h) 10.8 (5.3) 9.9 (3.9) 10.5 (3.9) 11.8 (4.9)
AUC0–t area under the plasma hydrocodone concentration-versus-time curve (AUC) from time 0 to the time of the last measurable concentration,
AUC0–2 AUC from time 0 to 2 h, AUC0–12 AUC from time 0 to 12 h, AUC0–? AUC from time 0 to infinity, Cmax maximum observed plasma
hydrocodone concentration, extrapolation 100 9 (AUC0–?–AUC0–t)/AUC0–?), ER extended-release, t elimination half-life, tmax time to
maximum observed plasma hydrocodone concentration
a Median (range) presented for tmax
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depression, including respiratory depression, hypotension,
profound sedation, or coma [12–15]. Furthermore, the
updated prescribing labels for morphine sulfate ER cap-
sules (Avinza, Ligand Pharmaceuticals, Inc., San Diego,
CA, USA) and oxymorphone hydrochloride ER tablets
(Opana ER, King Pharmaceuticals, Inc., Bristol, TN, USA)
now include black box warnings advising against the use of
alcohol when taking these products because of the risk of
dose dumping based on pharmacokinetic interactions [16,
17].
With the increased medication content required for ER
formulations, protection against accidental or intentional
dose dumping is needed because the rapid release of active
medication may increase toxicity [6]. In 2005, the US Food
and Drug Administration requested the removal of ER
hydromorphone HCl capsules (Palladone, Purdue Pharma
L.P., Stamford, CT, USA) from the market after a phar-
macokinetic study revealed a dose-dumping effect when
the medication was administered concomitantly with
alcohol [18]. The average peak hydromorphone concen-
tration increased six-fold when administered with 8 oz of
40 % alcohol compared with water [19]. A pharmacoki-
netic study of an ER formulation of morphine sulfate and
naltrexone hydrochloride showed that coadministration
with 40 % alcohol did not affect overall exposure, but did
result in a two-fold increase in mean peak plasma con-
centration of morphine compared with coadministration
with water and a reduction of time to reach peak plasma
concentration from 9 to 4 h, indicating an earlier release of



















Hydrocodone ER 15 mg
a
b
Fig. 4 Box and whisker plots of Cmax (a) and AUC0–? (b) data by
alcohol concentration. Horizontal line represents the median; boxes
represent 25th–75th percentiles (Q1–Q3); whiskers represent the
minimum and maximum within (Q1–1.5IQR, Q3 ? 1.5IQR); dia-
monds represent the mean; circles represent the outliers. AUC0–? area
under the plasma hydrocodone concentration-versus-time curve from
time 0 to infinity, Cmax maximum observed plasma hydrocodone
concentration, IQR interquartile range, Q quartile
Table 2 Analysis of variance ratios from geometric means of pharmacokinetic parameters: pharmacokinetic analysis set
Pharmacokinetic parameter Hydrocodone ER 15 mg Ratio (90 % CI)
4 % alcohol (n = 30) Water (n = 30)
Cmax (ng/mL) 13.2 12.4 1.05 (1.00, 1.10)
AUC0–? (ngh/mL) 207.6 191.3 1.07 (1.02, 1.12)
Hydrocodone ER 15 mg Ratio (90 % CI)
20 % alcohol (n = 27) Water (n = 27)
Cmax (ng/mL) 13.5 12.3 1.09 (1.04, 1.14)
AUC0–? (ngh/mL) 219.7 192.8 1.13 (1.07, 1.19)
Hydrocodone ER 15 mg Ratio (90 % CI)
40 % alcohol (n = 24) Water (n = 24)
Cmax (ng/mL) 13.3 11.8 1.14 (1.09, 1.20)
AUC0–? (ngh/mL) 212.9 186.3 1.17 (1.12, 1.22)
Values are geometric means
AUC0–? area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity, Cmax maximum observed plasma
hydrocodone concentration, ER extended-release
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Results from the present single-center, randomized,
open-label crossover study demonstrate that systemic
exposure (Cmax and AUC) was similar when hydrocodone
ER was administered with 240 mL water or orange juice
containing 4, 20, or 40 % alcohol, indicating that the risk
of alcohol-induced dose dumping associated with the use
of hydrocodone ER is low in a fasted state, even at high
levels of alcohol exposure (40 %). Furthermore, the com-
parable findings and lack of marked effect for other phar-
macokinetic parameters (e.g. tmax, t) for subjects
receiving alcohol or water suggest that concomitant alcohol
consumption has little or no effect on the overall pharma-
cokinetic profile of hydrocodone ER.
In the current study, hydrocodone ER was generally well
tolerated by these subjects who had been administered
naltrexone to limit opioid-related AEs. The majority of
AEs were mild to moderate in severity, and there were no
reports of serious AEs, deaths, or discontinuations due to
AEs that were treatment related. When given in combina-
tion with hydrocodone ER, the increasing incidence of AEs
associated with increasing concentrations of alcohol (4, 20,
40 %) was not unexpected and was likely attributable to
the incremental effects of administering the alcohol. Lastly,
no clinically significant respiratory depression was reported
during the study. Although clinically significant respiratory
rates were observed in 28 subjects (\10 breaths/min), data
from a separate phase 1 study of hydrocodone ER indicates
that clinically significant respiratory rate values were
reported both before and after administration of hydro-
codone ER and placebo with comparable incidence. As a
result, the clinically significant decreased respiratory rate
values observed for hydrocodone ER in the current study
are not necessarily considered to be related to administra-
tion of hydrocodone (data on file, Teva Pharmaceuticals,
Frazer, PA, USA).
5 Conclusion
Prescribers should continue to discourage consumption of
alcohol during any treatment with opioids. However,
results of this analysis provide insights into pharmacoki-
netic changes that may be anticipated if alcohol is con-
sumed by patients taking hydrocodone ER formulated with
CIMA ADT. Hydrocodone ER formulated with CIMA
ADT appears to be resistant to dose dumping when
administered with alcohol, as demonstrated by similar
systemic exposures after administration of hydrocodone
ER with increasing concentrations of alcohol (4, 20, and
40 %).
Acknowledgments This study was sponsored by Teva Pharma-
ceuticals (Frazer, PA, USA). Medical writing assistance was provided
by Bina Patel, PharmD, CMPP, of Peloton Advantage, LLC, and was
funded by Teva Branded Pharmaceutical Products R & D, Inc.
(Frazer, PA). Teva provided a full review of this article.
All authors were employees of Teva Pharmaceuticals Industries Ltd
at the time of this writing.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
Table 3 Adverse events occurring in C5 % of subjects in any treatment group: safety analysis set
Adverse event, n (%) Hydrocodone ER 15 mg
Water (n = 32) 4 % alcohol (n = 36) 20 % alcohol (n = 35) 40 % alcohol (n = 33)
Patients with C1 adverse event 11 (34) 9 (25) 20 (57) 20 (61)
Nausea 4 (13) 1 (3) 5 (14) 13 (39)
Headache 3 (9) 3 (8) 10 (29) 12 (36)
Vomiting 1 (3) 1 (3) 4 (11) 9 (27)
Feeling drunk 0 1 (3) 5 (14) 10 (30)
Dizziness 0 0 3 (9) 5 (15)
Paresthesia 0 0 5 (14) 6 (18)
Abdominal pain 1 (3) 3 (8) 3 (9) 0
Fatigue 1 (3) 1 (3) 2 (6) 2 (6)
Somnolence 2 (6) 1 (3) 1 (3) 1 (3)
Pain in extremity 1 (3) 0 2 (6) 0
Diarrhea 0 2 (6) 1 (3) 1 (3)
Diplopia 0 0 0 2 (6)
Tremor 2 (6) 0 0 0
ER extended release
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